This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a.. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Rosa Buonfiglio: Innovator in Glycogen Synthase Kinase 3 Beta Inhibitors
Introduction
Rosa Buonfiglio is a notable inventor based in Bologna, Italy. She has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target glycogen synthase kinase 3 beta (GSK-3β). Her work is crucial in addressing various health disorders.
Latest Patents
Rosa holds a patent for her invention titled "1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors." This invention relates to the use of these compounds in treating GSK-3β-related disorders, which include insulin-resistance disorders, neurodegenerative diseases, mood disorders, and several others. The patent highlights the potential of these compounds in addressing critical health issues.
Career Highlights
Rosa is associated with Aziende Chimiche Riunite Angelini Francesco A.c.r.a.f. S.p.a., where she continues to innovate and contribute to the field. Her work has garnered attention for its potential impact on treating complex diseases.
Collaborations
Rosa collaborates with esteemed colleagues such as Guido Furlotti and Claudia Cavarischia. Their combined expertise enhances the research and development efforts within their organization.
Conclusion
Rosa Buonfiglio's contributions to the field of medicinal chemistry, particularly through her patent on GSK-3β inhibitors, showcase her innovative spirit and dedication to improving health outcomes. Her work is a testament to the importance of research in addressing significant medical challenges.